Study Overview
This study looked at how effective intranasal oxytocin (40 IU) is when used with Alcohol Behavioral Couple Therapy (ABCT) for treating alcohol use disorder (AUD). It compared the effects of oxytocin to a placebo (saline).
Trial Details
The clinical trial lasted for 12 weeks and was conducted from 2018 to 2024. It was designed to be double-blind and randomized, meaning neither the participants nor the researchers knew who was receiving oxytocin or the placebo. A total of 96 couples (dyads) participated, with one partner diagnosed with AUD and the other partner included in the study. Both partners received the same treatment. Participants took the medication 30 minutes before therapy sessions.
Results Summary
Both groups showed improvements in alcohol consumption and severity of alcohol problems, but there was no significant improvement in relationship functioning. On average, participants attended 10.2 therapy sessions. There were no differences in the number of doses taken or any adverse effects between the oxytocin and placebo groups.
Conclusions
Oxytocin was found to be safe and tolerable, but it did not provide additional benefits when combined with ABCT. More research is needed to explore how oxytocin might aid recovery in different areas of AUD treatment.
Next Steps for Clinics and Patients
- Define Measurable Outcomes: Set clear goals for what you want to achieve with treatment.
- Select AI Tools: Identify AI solutions that can help with specific clinical needs.
- Implement Step by Step: Start with a pilot project to track results and see real-world impacts.
Contact Us for AI Solutions in Medical Management
For more information, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
